anonymous
Guest
anonymous
Guest
MannKind's so-far successful treprostinil formulation is getting a boost from United Therapeutics, that agreed to co-develop the drug under an exclusive global agreement. And, that is good news for those who find it difficult to get the right drug for pulmonary arterial hypertension.